TROP2-targeted monoclonal antibody linked via a cleavable linker to a topoisomerase I inhibitor. After binding TROP2 on tumor cells and internalization, the linker is cleaved to release the cytotoxic payload, causing DNA damage and apoptosis; membrane-permeable payload may enable a bystander effect on neighboring cells.